Development of a market relevant DNA nano-vaccine platform (2021-2025)
Abstract
DNA vaccine technology can potentially provide a rapid response to existing or new pathogens, but its market success has been limited. By addressing key scientific and technical challenges, this project aims to develop a new and cost-effective DNA nanovaccine platform using a multiscale engineering approach. It is anticipated that novel nanoparticles for DNA delivery and an end-user-driven DNA vaccine technology with enhanced immunogenicity, stability and safety will be generated. Expected outcomes include new knowledge in nanomaterial science and a market ready technology platform, improving Australia¿s capabilities in nanobiotechnology and vaccine development, as well as delivering a new value-added product for the Industry Partner.
